Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institut Claudius Regaud
Peking University Cancer Hospital & Institute
Prisma Health-Upstate
Children's National Research Institute
M.D. Anderson Cancer Center
Georgetown University
Peking University Cancer Hospital & Institute
Emory University
St. Jude Children's Research Hospital
Zhejiang University
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sichuan University
Hebei Medical University Fourth Hospital
Hebei Medical University Fourth Hospital
Gustave Roussy, Cancer Campus, Grand Paris
Memorial Sloan Kettering Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
Fox Chase Cancer Center
Massachusetts General Hospital
Shenzhen Geno-Immune Medical Institute
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Stanford University
University of California, San Francisco
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Medical College of Wisconsin
Chinese PLA General Hospital
University of Chicago
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
Universitair Ziekenhuis Brussel
Tianjin Medical University Second Hospital
European Institute of Oncology
The First Affiliated Hospital of Zhengzhou University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Uppsala University Hospital
Peking University Cancer Hospital & Institute
Peking University Cancer Hospital & Institute
Beidahuang Industry Group General Hospital
Fudan University
China Medical University, China
University of Texas Southwestern Medical Center
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
Sun Yat-sen University
University of Oklahoma
Institut de Cancérologie de Lorraine